Results 161 to 170 of about 14,094 (223)

Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE‐O Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims In the AMPLITUDE O trial, efpeglenatide reduced major cardiovascular events by 27% in 4076 individuals with Type 2 diabetes and established cardiovascular or kidney disease compared to placebo during a median follow‐up of 1.81 years. This exploratory mediation analysis evaluates the degree to which changes in measured clinical variables ...
Daniel Raaschou‐Oddershede, Christine R. Schwarz, Tanya Kovalova, Kelley R. Branch, Stefano Del Prato, Carolyn S. P. Lam, Renato D. Lopes, Richard Pratley, Julio Rosenstock, Naveed Sattar, Hertzel C. Gerstein   +10 more
wiley   +1 more source

A systematic review of semaglutide-associated kidney injury case reports. [PDF]

Front Med (Lausanne)
Xiu X, Zheng PP, Li Y, Du M, Min X, Pang X, Zhang L, Liu J, Zhao Z, Liu ZC, Feng CX.   +10 more
europepmc   +1 more source

Tirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the effect of tirzepatide on body weight, glycaemic control, insulin requirements, continuous glucose monitoring (CGM) metrics and cardiorenal parameters in adults with Type 1 diabetes (T1D) and overweight or obesity. Materials and Methods In this retrospective matched cohort study, adults with T1D, BMI ≥ 27 kg/m2, CGM use and
Amanda R. Purcell, Matilda S. G. Longfield, Natassia Rodrigo, Sarah J. Glastras   +3 more
wiley   +1 more source

Personalized Combination of a Ketogenic Diet and Low-Dose Semaglutide for Cardiometabolic Health: A Retrospective Case Series. [PDF]

J Pers Med
Parker G, Morris MD, Heggie JR, Cooper-Leavitt EF, Clark CJ, Reynolds AP, Smith HA, Wendel CP, Jensen WJ, Morris TJ, Reynolds PR, Bikman BT.   +11 more
europepmc   +1 more source

The Impact of Missed Doses on Pharmacokinetic Concentrations for Oral Semaglutide in Comparison to Other Glucagon‐Like Peptide‐1‐Based Therapies

Diabetes, Obesity and Metabolism, EarlyView.
Rune Viig Overgaard, Henrik Agersø, Christian Hollensen, Naveen Rathor, Eric M. Bomberg   +4 more
wiley   +1 more source

Semaglutide Injection Once‐Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active‐Controlled Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To evaluate and compare the efficacy, safety, and immunogenicity of a synthetic semaglutide injection (Test semaglutide) with Wegovy (Reference semaglutide) injection for weight management. Materials and Methods This randomized, Phase III, non‐inferiority study included adults with obesity or overweight with or without comorbidities from ...
Unnikrishnan Ambika Gopalakrishnan, Ameya Joshi, Harish Kumar, Richa Giri, Sanjiv Maheshwari, Valluri Satya Prasad, Jitendra Shukla, Rekha M. Chowdaiah, Nutan Kumar Agrawal, Yogesh Rasal, Banshidhar Sahoo, Shweta Bhandari, Ambanna Gowda, Uday Phadke, Pravin Supe, Niranjan Pathak, Ambrish Chandrappa, Ashutosh Sonawane, Yash Bahulikar, Amit Bhaskar, Arunkumar Radhakrishnan, Priyanka Yadav, Sucheta Pandit, Supriya Sonowal, Dipak Patil, Pravin Ghadge, Suyog Mehta   +26 more
wiley   +1 more source

Impact of semaglutide on liver fibrosis score in people with HIV: findings from the CNICS cohort. [PDF]

AIDS
Ma J, Ruderman SA, Haidar L, Delaney JA, Kim HN, Alba D, Crothers K, Eltonsy S, Heath S, Hwang YJ, Karris M, Mayer KH, Napravnik S, Pettit AC, Rodriguez A, Whitney BM, Yendewa G, Saag MS, Kitahata MM, Crane HM.   +19 more
europepmc   +1 more source

Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early‐Phase Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The management of the disease of obesity has been transformed by incretin‐based therapies; however, additional and alternative therapeutic strategies are needed to address its biological complexity. This narrative review examines the physiology of amylin and the emerging role of amylin‐based therapies in obesity management.
Abdulhameed Alhazmi, Carel W. le Roux
wiley   +1 more source

Ketoacidosis Risk in Non-diabetic Patients Using Semaglutide Versus Tirzepatide for Obesity: A Disproportionality Analysis of the FDA Adverse Event Reporting System. [PDF]

Cureus
Makhmutov A, Qureshi F.
europepmc   +1 more source

Early Weight Regain After GLP‐1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De‐Escalation Strategies

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have transformed the pharmacological management of obesity, producing substantial and sustained weight loss during active treatment. However, discontinuation of therapy is frequently followed by significant weight regain, raising important questions regarding the durability of treatment ...
M. A. Damhof, F. H. van Bruggen, E. N. van Roon   +2 more
wiley   +1 more source